<?xml version="1.0" encoding="UTF-8"?>
<p>Over the last four decades, increasing numbers of fungal biomarkers have been added to the roster of tests available as aids to the diagnosis of invasive fungal disease (IFD) [
 <xref rid="B1-jof-07-00014" ref-type="bibr">1</xref>,
 <xref rid="B2-jof-07-00014" ref-type="bibr">2</xref>,
 <xref rid="B3-jof-07-00014" ref-type="bibr">3</xref>]. Among these is (1→3)-β-glucan, a cell wall component of almost all pathogenic fungi, with the exception of the 
 <italic>Mucorales</italic> [
 <xref rid="B4-jof-07-00014" ref-type="bibr">4</xref>,
 <xref rid="B5-jof-07-00014" ref-type="bibr">5</xref>]. At this point, analysis of circulating titers of (1→3)-β-
 <sc>d</sc>-glucan (BDG) has been practiced for almost three decades, as an adjunct to the diagnosis of IFD [
 <xref rid="B6-jof-07-00014" ref-type="bibr">6</xref>]. The BDG test offers a relatively simple, non-invasive opportunity to obtain information on a near pan-fungal biomarker with demonstrated relevance to IFD diagnosis and, importantly, anti-fungal stewardship [
 <xref rid="B7-jof-07-00014" ref-type="bibr">7</xref>,
 <xref rid="B8-jof-07-00014" ref-type="bibr">8</xref>]. As such, over the years, it has been incorporated into an increasing number of clinical guidelines and routine practice algorithms [
 <xref rid="B9-jof-07-00014" ref-type="bibr">9</xref>,
 <xref rid="B10-jof-07-00014" ref-type="bibr">10</xref>].
</p>
